• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

泌尿系统感染中耐碳青霉烯类及产超广谱β-内酰胺酶的多重耐药大肠杆菌的流行情况及基因组分析

Prevalence and genomic insights of carbapenem resistant and ESBL producing Multidrug resistant Escherichia coli in urinary tract infections.

作者信息

Sivarajan Vidhyalakshmi, Ganesh Amirtha Varshini, Subramani Pavithra, Ganesapandi Priyanka, Sivanandan R N, Prakash Sneha, Manikandan Nithyasri, Dharmarajan Arunasalam, Arfuso Frank, Warrier Sudha, Raj Marquess, Perumal Kumar

机构信息

Department of Biotechnology, Faculty of Biomedical Sciences and Technology, Sri Ramachandra Institute of Higher Education and Research (SRIHER), Porur, Chennai, India.

Division of Infectious Disease, St. John's Research Institute, Bangalore, Karnataka, India.

出版信息

Sci Rep. 2025 Jan 20;15(1):2541. doi: 10.1038/s41598-024-84754-w.

DOI:10.1038/s41598-024-84754-w
PMID:39833199
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11747333/
Abstract

Urinary tract infections are a common condition affecting people globally, with multidrug-resistant (MDR) Escherichia coli (E. coli) being a major causative agent. Antimicrobial susceptibility profiling was performed using the VITEK 2 automated system for 1254 E. coli isolates, revealing that 831(66.2%) isolates were determined as MDR E. coli. A significant resistance pattern was observed for nalidixic acid (86.04%), ampicillin (74.16%), ticarcillin (70.73%), cefalotin (65.23%), cefixime (62.68%), ciprofloxacin (55.18%), ceftriaxone (53.75%), amoxicillin-clavulanic acid (22.81%), ertapenem (7.18%), and fosfomycin (2.23%). Whole Genome Sequencing of Carbapenem-resistant E. coli (CREC)-CREC 3 (ST405), CREC 4 (ST448), and CREC 5 (ST167) was performed to determine genomic characteristics. CREC 3, CREC 4, and CREC 5 belong to the phylogroup D, B1, and A, respectively. The NDM-5 gene was common in all three isolates, with CTX-M-15 being present in CREC 3 and CREC 4. Virulence factors of CREC 3 (fliC, shuA), CREC 4 (spaS), CREC 5 (iucA, papH, papG, iucB, yigF), and plasmids (IncFIA, IncFIB) were identified to be significant. The use of pangenome analysis enhances our understanding of resistance traits of isolates ST167, ST405, and ST448, offering valuable insights into comparative genomics of uropathogenic MDR E. coli.

摘要

尿路感染是一种影响全球人群的常见疾病,多重耐药(MDR)大肠杆菌(E. coli)是主要病原体。使用VITEK 2自动化系统对1254株大肠杆菌分离株进行了药敏分析,结果显示831株(66.2%)分离株被确定为多重耐药大肠杆菌。观察到对萘啶酸(86.04%)、氨苄西林(74.16%)、替卡西林(70.73%)、头孢噻吩(65.23%)、头孢克肟(62.68%)、环丙沙星(55.18%)、头孢曲松(53.75%)、阿莫西林-克拉维酸(22.81%)、厄他培南(7.18%)和磷霉素(2.23%)存在显著的耐药模式。对耐碳青霉烯类大肠杆菌(CREC)——CREC 3(ST405)、CREC 4(ST448)和CREC 5(ST167)进行了全基因组测序,以确定其基因组特征。CREC 3、CREC 4和CREC 5分别属于D、B1和A系统发育群。NDM-5基因在所有三株分离株中都很常见,CTX-M-15存在于CREC 3和CREC 4中。已确定CREC 3(fliC、shuA)、CREC 4(spaS)、CREC 5(iucA、papH、papG iucB、yigF)的毒力因子以及质粒(IncFIA、IncFIB)具有重要意义。泛基因组分析的应用增进了我们对ST167、ST405和ST448分离株耐药特性的理解,为尿路致病性多重耐药大肠杆菌的比较基因组学提供了有价值的见解。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3d/11747333/e47ab3d3e5b6/41598_2024_84754_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3d/11747333/55f60ed346a2/41598_2024_84754_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3d/11747333/3ce93bb91523/41598_2024_84754_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3d/11747333/f2dec00dee95/41598_2024_84754_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3d/11747333/eb54c0768faf/41598_2024_84754_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3d/11747333/1c18e3464a21/41598_2024_84754_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3d/11747333/e47ab3d3e5b6/41598_2024_84754_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3d/11747333/55f60ed346a2/41598_2024_84754_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3d/11747333/3ce93bb91523/41598_2024_84754_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3d/11747333/f2dec00dee95/41598_2024_84754_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3d/11747333/eb54c0768faf/41598_2024_84754_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3d/11747333/1c18e3464a21/41598_2024_84754_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b3d/11747333/e47ab3d3e5b6/41598_2024_84754_Fig6_HTML.jpg

相似文献

1
Prevalence and genomic insights of carbapenem resistant and ESBL producing Multidrug resistant Escherichia coli in urinary tract infections.泌尿系统感染中耐碳青霉烯类及产超广谱β-内酰胺酶的多重耐药大肠杆菌的流行情况及基因组分析
Sci Rep. 2025 Jan 20;15(1):2541. doi: 10.1038/s41598-024-84754-w.
2
The emergence of highly resistant and hypervirulent ST405 clone in a tertiary hospital over 8 years.8年间,一家三级医院出现了高度耐药和高毒力的ST405克隆株。
Emerg Microbes Infect. 2025 Dec;14(1):2479048. doi: 10.1080/22221751.2025.2479048. Epub 2025 Mar 24.
3
Molecular Characterization of Escherichia coli Causing Community-Acquired Urinary Tract Infections in a Suburban Area in West Bengal, India: Dispersal of Multidrug-Resistant Epidemic ST131 Clone Carrying CTX-M-1.印度西孟加拉邦一个郊区社区获得性尿路感染大肠杆菌的分子特征:携带CTX-M-1的多重耐药流行ST131克隆的传播
Curr Microbiol. 2025 May 23;82(7):303. doi: 10.1007/s00284-025-04271-5.
4
Emergence of Carbapenem-Resistant Uropathogenic (ST405 and ST167) Strains Carrying , and Diverse Virulence Factors in Hospitalized Patients.携带blaCTX-M-15、blaOXA-48和多种毒力因子的耐碳青霉烯类尿路致病性(ST405和ST167)菌株在住院患者中的出现。
Pathogens. 2024 Nov 5;13(11):964. doi: 10.3390/pathogens13110964.
5
Clinical risk factors and outcomes of carbapenem-resistant nosocomial infections in a Chinese teaching hospital: a retrospective study from 2013 to 2020.中文译文:中国教学医院碳青霉烯类耐药医院感染的临床危险因素和结局:2013 年至 2020 年的回顾性研究。
Microbiol Spectr. 2024 Jul 2;12(7):e0422823. doi: 10.1128/spectrum.04228-23. Epub 2024 May 30.
6
KpnK48 clone driving hypervirulent carbapenem-resistant Escherichia coli epidemics: Insights into its evolutionary trajectory similar to Klebsiella pneumoniae.驱动高毒力耐碳青霉烯类大肠杆菌流行的KpnK48克隆:对其与肺炎克雷伯菌相似的进化轨迹的见解
Drug Resist Updat. 2025 Jul;81:101243. doi: 10.1016/j.drup.2025.101243. Epub 2025 Apr 8.
7
Risk factors and molecular characterization of carbapenem resistant Escherichia coli recovered from a tertiary hospital in Fujian, China from 2021 to 2023.2021 年至 2023 年期间从中国福建一家三级医院回收的耐碳青霉烯类大肠埃希菌的危险因素和分子特征。
BMC Microbiol. 2024 Sep 28;24(1):374. doi: 10.1186/s12866-024-03525-9.
8
Emergence of a clinical carbapenem-resistant Escherichia coli co-harboring bla and mcr-1.1 on the same plasmid.同一质粒上同时携带bla和mcr-1.1的临床耐碳青霉烯类大肠杆菌的出现。
Int J Antimicrob Agents. 2025 Jul;66(1):107495. doi: 10.1016/j.ijantimicag.2025.107495. Epub 2025 Mar 24.
9
Spread of the Fosfomycin resistance fosA3 gene via the IS26 mobile element between plasmids and the chromosome of carbapenem-resistant Escherichia coli in China.中国碳青霉烯耐药大肠埃希菌中磷霉素耐药基因fosA3通过IS26移动元件在质粒与染色体之间的传播。
J Glob Antimicrob Resist. 2025 May;42:80-87. doi: 10.1016/j.jgar.2025.02.011. Epub 2025 Feb 22.
10
Rapid Dissemination of Gene among Carbapenem-Resistant Isolates in a Yellow-Feather Broiler Farm via Multiple Plasmid Replicon.基因通过多个质粒复制子在一个黄羽肉鸡场的耐碳青霉烯类分离株中快速传播。
Pathogens. 2024 May 7;13(5):387. doi: 10.3390/pathogens13050387.

引用本文的文献

1
Enteroaggregative foodborne outbreak in Shandong Province, China (2023): comprehensive epidemiology and genomic resistance profiling.中国山东省食源性聚集性疫情(2023年):综合流行病学及基因组耐药性分析
Front Microbiol. 2025 Jun 27;16:1577277. doi: 10.3389/fmicb.2025.1577277. eCollection 2025.

本文引用的文献

1
Emergence of Carbapenem-Resistant Uropathogenic (ST405 and ST167) Strains Carrying , and Diverse Virulence Factors in Hospitalized Patients.携带blaCTX-M-15、blaOXA-48和多种毒力因子的耐碳青霉烯类尿路致病性(ST405和ST167)菌株在住院患者中的出现。
Pathogens. 2024 Nov 5;13(11):964. doi: 10.3390/pathogens13110964.
2
The Prevalence of Multidrug-Resistant in Chennai and Whole Genome Sequence Analysis of Carbapenem-Resistant ST410.钦奈多重耐药菌的流行情况及耐碳青霉烯类 ST410 的全基因组序列分析
Indian J Microbiol. 2024 Jun;64(2):467-474. doi: 10.1007/s12088-023-01125-1. Epub 2023 Nov 28.
3
Regional variations in antimicrobial susceptibility of community-acquired uropathogenic in India: Findings of a multicentric study highlighting the importance of local antibiograms.
印度社区获得性尿路致病性细菌抗菌药物敏感性的区域差异:一项多中心研究的结果凸显了当地抗菌谱的重要性。
IJID Reg. 2024 Apr 25;11:100370. doi: 10.1016/j.ijregi.2024.100370. eCollection 2024 Jun.
4
Molecular Characterization of Escherichia coli Causing Urinary Tract Infections Through Next-Generation Sequencing: A Comprehensive Analysis of Serotypes, Sequence Types, and Antimicrobial and Virulence Genes.通过下一代测序对引起尿路感染的大肠杆菌进行分子特征分析:血清型、序列类型以及抗菌和毒力基因的综合分析
Cureus. 2024 Mar 5;16(3):e55556. doi: 10.7759/cureus.55556. eCollection 2024 Mar.
5
Multidrug resistance among uropathogenic clonal group A E. Coli isolates from Pakistani women with uncomplicated urinary tract infections.巴基斯坦单纯性尿路感染女性患者中产志贺邻单胞菌群 A 尿源性病原体分离株的多重耐药性。
BMC Microbiol. 2024 Mar 7;24(1):74. doi: 10.1186/s12866-024-03221-8.
6
Characterization of uropathogenic from various geographical locations in India.对来自印度不同地理位置的尿路致病性病菌的特征分析。
J Taibah Univ Med Sci. 2023 Jul 20;18(6):1527-1535. doi: 10.1016/j.jtumed.2023.07.003. eCollection 2023 Dec.
7
Urinary Tract Infections Caused by Uropathogenic : Mechanisms of Infection and Treatment Options.尿路感染的病原体:感染机制和治疗选择。
Int J Mol Sci. 2023 Jun 23;24(13):10537. doi: 10.3390/ijms241310537.
8
Phenotypic and molecular characterization of beta-lactam resistant Multidrug-resistant Enterobacterales isolated from patients attending six hospitals in Northern Nigeria.尼日利亚北部六家医院就诊患者中分离出的耐β-内酰胺的多药耐药肠杆菌科的表型和分子特征。
Sci Rep. 2023 Jun 26;13(1):10306. doi: 10.1038/s41598-023-37621-z.
9
Genome profiling of uropathogenic E. coli from strictly defined community-acquired UTI in paediatric patients: a multicentric study.对儿科患者严格定义的社区获得性尿路感染的尿路致病性大肠杆菌的基因组分析:一项多中心研究。
Antimicrob Resist Infect Control. 2023 Apr 18;12(1):36. doi: 10.1186/s13756-023-01233-z.
10
Fluoroquinolones Are Useful as Directed Treatment for Complicated UTI in a Setting with a High Prevalence of Quinolone-Resistant Microorganisms.在喹诺酮耐药微生物高流行的情况下,氟喹诺酮类药物可作为复杂性尿路感染的直接治疗药物。
Antibiotics (Basel). 2023 Jan 16;12(1):183. doi: 10.3390/antibiotics12010183.